GM potatoes and the implications for pharma
This article was originally published in Scrip
Executive Summary
Genetically modified potatoes might not appear at first sight to be a matter of more than passing interest to observers of the pharmaceutical scene. But the European Commission's go-ahead this week for cultivation of the first GM potato – also the first GMO authorisation in the EU since 1998 – has a number of implications for pharma firms working in Europe.